News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Kollins John A
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/08/2023 |
4
| Kollins John A (President and CEO) has filed a Form 4 on Satsuma Pharmaceuticals, Inc.|
Txns:
| Unknown transaction of 305,911 shares
@ $0.91, valued at
$278.4k
Disposed/sold 175,000 options to buy
@ $29, valued at
$5.1M
Disposed/sold 240,000 options to buy
@ $4.6, valued at
$1.1M
Disposed/sold 505,000 options to buy
@ $3.46, valued at
$1.7M
Disposed/sold 276,595 options to buy
@ $4.56, valued at
$1.3M
Disposed/sold 127,659 options to buy
@ $1.04, valued at
$132.8k
Disposed/sold 127,659 options to buy
@ $0.9, valued at
$114.9k
|
|
| 06/07/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/07/2020 |
4
| Kollins John A (President and CEO) has filed a Form 4 on Satsuma Pharmaceuticals, Inc.|
Txns:
| Granted 240,000 options to buy
@ $4.6, valued at
$1.1M
|
|
| 03/06/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/12/2019 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 10/30/2014 |
4
| Kollins John A (SVP, Chief Business Officer) has filed a Form 4 on Transcept Pharmaceuticals Inc|
Txns:
| Granted 4,161 shares
@ $21.588, valued at
$89.8k
Disposed/sold 4,166 options to buy
@ $0
Disposed/sold 7,083 options to buy
@ $0
Disposed/sold 7,500 options to buy
@ $0
Disposed/sold 9,583 options to buy
@ $0 |
|
| 06/05/2014 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 07/18/2013 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 01/08/2013 |
4
| Kollins John A (SVP, Chief Business Officer) has filed a Form 4 on Transcept Pharmaceuticals Inc|
Txns:
| Granted 90,000 options to buy
@ $5.4, valued at
$486k
|
|
| 06/21/2012 |
4
| Kollins John A (SVP, Chief Business Officer) has filed a Form 4 on Transcept Pharmaceuticals Inc|
Txns:
| Granted 85,000 options to buy
@ $6.11, valued at
$519.4k
|
|
| 06/04/2012 |
3
| Kollins John A (SVP, Chief Business Officer) has filed a Form 3 on Transcept Pharmaceuticals Inc |
| 01/22/2009 |
4
| Kollins John A (CEO) has filed a Form 4 on OXIGENE INC |
| 12/18/2008 |
4
| Kollins John A (CEO) has filed a Form 4 on OXIGENE INC |
|
|